Palvella Therapeutics PVLA
NASDAQ PVLA
$140.51 +1.51 (+1.09%)
As of: Sep 30, 2026 · 3:53 PM EDT

Palvella Therapeutics (PVLA) EV to EBITDA (2024)

Updated

Palvella Therapeutics' (PVLA) EV to EBITDA came in at 0.73 for Q3 2024.

Analysis

Palvella Therapeutics (PVLA) EV to EBITDA (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Palvella Therapeutics 2.00 Bn 1.75 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 0.73
Mar 31, 2024 0.07
API Access

Palvella Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=PVLA&period=max&api_key=YOUR_API_KEY